FDA Approval Alert: The Need-to-Know | Selpercatinib in RET+ Thyroid Cancer

In June 2024, the FDA granted full approval to selpercatinib as a treatment for patients 2 years and older with RET fusion-positive advanced or metastatic thyroid cancer.

Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Selpercatinib Earns Full FDA Approval Status in RET+ Thyroid Cancer
Article
Jun 12, 2024 6:52 PM
Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
Selpercatinib Earns Accelerated Approval in Pediatric RET+ Thyroid Cancer
Article
May 29, 2024 4:27 PM
Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.